The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Abstract Text:

BACKGROUND: Carbamazepine is widely accepted as a drug of first choice for patients with partial onset seizures. Several newer drugs possess efficacy against these seizure types but previous randomised controlled trials have failed to inform a choice between these drugs. We aimed to assess efficacy with regards to longer-term outcomes, quality of life, and health economic outcomes. METHODS: SANAD was an unblinded randomised controlled trial in hospital-based outpatient clinics in the UK. Arm A recruited 1721 patients for whom carbamazepine was deemed to be standard treatment, and they were randomly assigned to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate. Primary outcomes were time to treatment failure, and time to 12-months remission, and assessment was by both intention to treat and per protocol. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN38354748. FINDINGS: For time to treatment failure, lamotrigine was significantly better than carbamazepine (hazard ratio [HR] 0.78 [95% CI 0.63-0.97]), gabapentin (0.65 [0.52-0.80]), and topiramate (0.64 [0.52-0.79]), and had a non-significant advantage compared with oxcarbazepine (1.15 [0.86-1.54]). For time to 12-month remission carbamazepine was significantly better than gabapentin (0.75 [0.63-0.90]), and estimates suggest a non-significant advantage for carbamazepine against lamotrigine (0.91 [0.77-1.09]), topiramate (0.86 [0.72-1.03]), and oxcarbazepine (0.92 [0.73-1.18]). In a per-protocol analysis, at 2 and 4 years the difference (95% CI) in the proportion achieving a 12-month remission (lamotrigine-carbamazepine) is 0 (-8 to 7) and 5 (-3 to 12), suggesting non-inferiority of lamotrigine compared with carbamazepine. INTERPRETATION: Lamotrigine is clinically better than carbamazepine, the standard drug treatment, for time to treatment failure outcomes and is therefore a cost-effective alternative for patients diagnosed with partial onset seizures.

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Publishing Authors By Initials

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Lancet

VOLUME: 369

Page Numbers: 1000-15

Journal Abbreviation: Lancet

ISSN: 1474-547X

DAY: 24

MONTH: Mar

YEAR: 2007

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2985213

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: drug therapy

Chemical & Substance for Abstract: The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Information

Substance Name: Anticonvulsants

Registry Number: 0

Grant and Affiliation Information for The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.

AFFILIATION: Division of Neurological Science, University of Liverpool, UK. a.g.marson@liv.ac.uk

Country: England

AGENCY: United Kingdom Department

GRANT: HTA_485

ACRONYM:

MEDLINETA: Lancet

REFSOURCE: Nat Clin Pract Neurol. 2007 Sep;3(9):484

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial Related Publications

• A practical approach to computing power for generalized linear models with nominal, count, or ordinal responses.
• Approximation algorithms.
• Association of depression with Body Mass Index, sedentary behavior, and maladaptive eating attitudes and behaviors in 11 to 13-year old children.
• Cell wall targeting of laccase of Cryptococcus neoformans during infection of mice.
• Composition of Agathosma capensis Essential Oil.
• Copper induces conformational changes in the N-terminal part of cell-surface PrPC.
• Correlates of health-related quality of life in overweight and obese adults with type 2 diabetes.
• Disuse atrophy of the intestinal tract.
• Image reconstruction for transmission tomography when projection data are incomplete.
• Inhibition of Plasmodium falciparum oocyst production by membrane-permeant cysteine protease inhibitor E64d.
• Measurement of children's food intake with digital photography and the effects of second servings upon food intake.
• Measurement of long-range 1H-19F scalar coupling constants and their glycosidic torsion dependence in 5-fluoropyrimidine-substituted RNA.
• On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis.
• Pose estimation of known objects during transmission tomographic image reconstruction.
• Properties of preprocessed sinogram data in x-ray computed tomography.
• Prospects for quantitative two-dimensional radiochromic film dosimetry for low dose-rate brachytherapy sources.
• Reformulation of the Children's Eating Attitudes Test (ChEAT): factor structure and scoring method in a non-clinical population.
• Role of a CUF1/CTR4 copper regulatory axis in the virulence of Cryptococcus neoformans.
• Role of a VPS41 homologue in starvation response, intracellular survival and virulence of Cryptococcus neoformans.
• Roles for mannitol and mannitol dehydrogenase in active oxygen-mediated plant defense.
• Seasonal influences on conception efficiency in Minnesota dairy herds.
• Statistical reconstruction for x-ray computed tomography using energy-integrating detectors.
• The Hsp70 member, Ssa1, acts as a DNA-binding transcriptional co-activator of laccase in Cryptococcus neoformans.
• The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial.
• The agreement between cervical abnormalities identified by cytology and detection of high-risk types of human papillomavirus.
• The impact of new ways of working on the job satisfaction of radiotherapy treatment radiographers.
• The regulation of substrate utilization.
• Toward molecular dissection of PrPC-PrPSc interactions.
• Values anglo-american and mexican-american mothers hold for their children with physical disabilities.
• Weight-related concerns associated with smoking in young children.